Valuation: Norda ASA

Market Cap 513M 52.4M 45.85M 42.26M 39.17M 74.35M 4.97B 75.55M 507M 197M 2.45B 197M 192M 8.48B P/E 2023 *
-
P/E 2024 3.26x
Enterprise Value 264M 26.99M 23.62M 21.77M 20.18M 38.3M 2.56B 38.92M 261M 102M 1.26B 101M 99.14M 4.37B EV / Sales 2023
-1.24x
EV / Sales 2024 0.4x
Free-Float
6.26%
Yield 2023 *
-
Yield 2024 32.5%
1 day+1.53%
3 months+1.53%
6 months-13.60%
Current year-13.60%
Current year 81
Extreme 81
86.4
1 year 80.1
Extreme 80.1
100
3 years 41
Extreme 41
100
5 years 41
Extreme 41
100
10 years 8
Extreme 8
100
Manager TitleAgeSince
Chief Executive Officer - 07/04/2013
Director TitleAgeSince
Director/Board Member 68 19/06/2013
Chairman 54 30/01/2014
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+1.53%-.--%+8.00%+110.73% 45.12M
-1.03%+5.24%+2.94%+9.41% 50.25B
+0.08%+2.06%+421.26%+624.31% 40.39B
+0.72%+7.94%+28.38%-3.81% 34.38B
-0.99%+7.99%+27.70%+62.36% 34.4B
+1.31%-0.56%+5.12%+33.90% 26.32B
+0.33%+1.44% - - 16.64B
-3.39%+3.42%+71.75%+132.55% 16.14B
+0.32%+0.53%+14.33%+21.47% 13.71B
+3.48%+8.80%+106.49%+106.49% 13.75B
Average +0.33%+3.42%+76.22%+121.93% 24.6B
Weighted average by Cap. +0.05%+4.10%+96.10%+141.68%

Financials

2023 2024
Net sales 86.92M 8.87M 7.77M 7.16M 6.63M 12.59M 842M 12.8M 85.82M 33.38M 416M 33.32M 32.6M 1.44B 372M 37.97M 33.22M 30.62M 28.38M 53.88M 3.6B 54.74M 367M 143M 1.78B 143M 139M 6.15B
Net income 31.17M 3.18M 2.79M 2.57M 2.38M 4.52M 302M 4.59M 30.78M 11.97M 149M 11.95M 11.69M 515M 126M 12.86M 11.25M 10.37M 9.61M 18.25M 1.22B 18.54M 124M 48.36M 602M 48.28M 47.23M 2.08B
Net Debt -311M -31.78M -27.81M -25.63M -23.75M -45.09M -3.02B -45.82M -307M -120M -1.49B -119M -117M -5.14B -249M -25.4M -22.23M -20.49M -18.99M -36.05M -2.41B -36.63M -246M -95.54M -1.19B -95.38M -93.31M -4.11B
Logo Norda ASA
Norda ASA, formerly NorDiag ASA, is a Norway-based company active within the biotechnology sector. It develops, manufactures and markets automated solutions (instruments and tests) for sample preparation of bacterial and human DNA from difficult biological samples for use in the fields of infectious diseases, transplantation testing (HLA Typing) and others. The Company’s products include NorDiag Arrow (CE, IVD), which is a compact, automated solution for nucleic acid extractions, as well as NorDiag Bullet, 8 tip config, which is a fully automated sample preparation instrument for molecular diagnostics and can isolate from samples such as urine, swab, faces, sputum and blood. Its distribution products include Molzym GmbH and Co KG, as well as Hain Lifescience GmbH. Its customers are clinical laboratories, hospitals, research institutes, medical diagnostics and healthcare providers. It is operational through offices and laboratories in Norway, Sweden, Austria and the United States.
Employees
1
  1. Stock Market
  2. Stocks
  3. NORD Stock